Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. EMEA/
      2. Our innovation /
      3. Focus areas/
      4. Oncology /
      5. Lung cancer

      Lung cancer

      Lung cancer is the leading cause of global cancer incidence and mortality.[1] In Europe, there were >484,000 lung cancer diagnoses in 2022. Non-small cell lung cancer (NSCLC) makes up about 85% of all lung cancers. Most people (up to 70%) with NSCLC present with advanced stage unresectable disease at diagnosis.[2][3]
      lung_banner.jpg
      At Johnson & Johnson, we innovate with the purpose to lead where medicine is going, as we work every day to get in front of cancer.[4] We focus on areas of greatest unmet need where we believe we can disrupt and truly transform cancer care. We are advancing a robust pipeline using differentiated scientific and innovative approaches, with the ambition to change and save lives.[5]

      Precision medicine is central to our approach, which can help healthcare providers identify disease and at-risk patient populations earlier and more specifically, ensuring that any treatment prescribed has the best chance of working.[6][7][8][9][10]
      With new molecular subtypes continuing to be discovered and expanding availability of tailored treatment options, earlier diagnoses and biomarker testing are increasingly vital to guide optimal, targeted treatment based on the disease profile for each individual patient.[11][12][13] However, despite clinical guidelines reinforcing the critical role of biomarker testing, challenges in availability, access and timeliness of testing mean that testing is not always possible.[12]

      At Johnson & Johnson we extensively invest in research & development to accelerate the discovery, development, and delivery of therapies that may help deepen responses and remissions as we aim to offer patients hope and time by driving toward a future with a cure for cancer.[14]

      We are committed to leading a paradigm shift in the treatment of lung cancer, the second most common cancer in both men and women. Our strategy involves targeting the complex nature of the disease by interfering with multiple disease mechanisms.[2][15]

      The five-year NSCLC survival rate is 25% and can vary based on multiple factors such as subtype and disease progress.[16] Targeted therapies can help people with NSCLC live longer, with a better quality of life.[17] NSCLC can be driven by a range of different mutations, with different characteristics.[17] EGFR (epidermal growth factor receptor) mutations are one of the most common types of genetic mutations in NSCLC.[18][19]
      The role of EGFR mutations in NSCLC

      EGFR-mutated NSCLC refers to a subtype of lung cancer characterised by specific mutations in the EGFR gene.[18] EGFR, a receptor tyrosine kinase, plays a role in regulating cell growth and division.[18] When mutations occur in the gene, they can lead to overactivation of the EGFR signalling pathway, promoting cancer cell growth and survival.[18]

      There are different types of EGFR mutations.[20] EGFR exon 19 deletions and exon 21 (L858R) substitution mutations are the most common, accounting for approximately 80-90% of mutations.[20] Exon 20 insertion mutations are the third most prevalent primary EGFR mutation, comprising up to 12% of cases and are known to be associated with poor survival outcomes.[21][22]

      Patients with EGFR exon 20 insertion mutations have poor survival rates, with a real-world five-year overall survival (OS) of 8% in the frontline setting, which is worse than patients with EGFR exon 19 deletions or L858R substitution mutations, who have a real-world five-year OS of 19%.[23][24]

      There is an urgent need for novel targeted therapies to combat resistance and disease progression, prolong survival, and offer alternative treatment options for those with EGFR-mutated NSCLC.[25][26]
      The role of EGFR mutations in NSCLC
      At Johnson & Johnson, we are dedicated to advancing the science and bringing forward transformative innovations to tackle unmet needs in lung cancer, the world’s leading cause of cancer mortality. We are pushing boundaries to deliver more personalised and targeted solutions for those who need them most. Our goal is not only to extend life expectancy but also to enhance the quality of life for patients.”
      Henar Hevia
      Ph.D., Senior Director, EMEA Therapy Area Head, Oncology
      We collaborate to innovate
      Based upon our belief that collaboration is essential to drive change and innovation, we are dedicated to building strategic collaborations across the globe. We invest our time, expertise and resources, and together with collaborators, seek to unlock the potential around us, all in pursuit of better outcomes for patients and their families.

      One example is Talk Lung Cancer, an educational programme created to provide helpful guidance and resources for people living with lung cancer, as well as their caregivers and loved ones. This support programme, developed alongside members of the lung cancer community and healthcare professionals, aims to address challenges around the disease, supporting understanding and empowering more open conversations on important topics.
      More from oncology at Johnson & Johnson Innovative Medicine EMEA

      References

      [1] World Health Organization. Lung Cancer. 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/lung-cancer#:~:text=Key%20facts,approximately%2085%25%20of%20all%20cases.
      [2] Globocan 2022. International Agency for Research on Cancer. Cancer Today online analysis table – lung cancer incidence in 2022, both sexes, in Europe. Available at: https://gco.iarc.fr/today/en/dataviz/tables?mode=cancer&group_populations=1&multiple_populations=1&populations=908.
      [3] Molina JR, et al. Non-small Cell Lung cancer: epidemiology, Risk factors, treatment, and Survivorship. Mayo Clinic Proceedings. 2008;83(5):584-594.
      [4] Nature. Janssen Oncology—leading the way in transformational innovation. Available at: https://www.nature.com/articles/d43747-022-00205-3.
      [5] Investor Johnson & Johnson. Development Pipeline. Available at: https://www.investor.jnj.com/pipeline/development-pipeline/default.aspx.
      [6] van der Velden DL, et al. Molecular Tumor Boards: current practice and future needs. Annals of Oncology. 2017;28:3070–3075.
      [7] PMC. Personalized Medicine at FDA. Available at: https://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/Personalized_Medicine_at_FDA_The_Scope_Significance_of_Progress_in_2021.pdf.
      [8] PMC. The Congressional Personalized Medicine Caucus. Available at: https://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/The_Congressional_PM_Caucus.pdf.
      [9] European Federation of Pharmaceutical Industries and Associations. Unlocking the potential of precision medicine in Europe. Policy recommendations February 2021. Available at: https://www.efpia.eu/media/589727/unlocking-the-potential-of-precision-medicine-in-europe.pdf.
      [10] Vanderpoel J, et al. Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer. J Med Econ. 2022;25:457–468.
      [11] Planchard D et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Suppl 4):iv192-iv237.
      [12] Lee DH, et al. Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study. PLoS ONE. 2018;13(8):e0202865.
      [13] Jackson SE, Chester JD. Personalised cancer medicine. Int J Cancer. 2015;137:262–266.
      [14] Janssen 2022 Transparency Report. Available at: https://transparencyreport.janssen.com/.
      [15] Cancer.Net. Lung Cancer - Non-Small Cell: Statistics. Available: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics.
      [16] Yao Y, Fareed R, Zafar A, Saleem K, Huang T, Duan Y, Rehman MU. State-of-the-art combination treatment strategies for advanced stage non-small cell lung cancer. Front Oncol. 2022 Aug 1;12:958505. doi: 10.3389/fonc.2022.958505.
      [17] Dong J, et al. Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing. Front. Pharmacol. 2019; 10:230.
      [18] Zappa A, Mousa S. Transl Lung Cancer Res. 2016 Jun;5(3):288-300. Doi: 10.21037/tlcr.2016.06.07.
      [19] Li Y, et al. Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA. PLoS One. 2019 Jan 4;14(1):e0209709. Doi: 10.1371/journal.pone.0209709.
      [20] Batra U, et al. Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer. BMJ Open Respir Res. 2023 Jun;10(1).
      [21] Oxnard GR, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb;8(2):179-84. Doi: 10.1097/JTO.0b013e3182779d18.
      [22] Burnett H, et al. Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review. PLoS One. 2021 Mar 8;16(3):e0247620.
      [23] Bazhenova L, et al. Lung Cancer. 2021;162:154-161.
      [24] Lin JJ, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016;11(4):556-65.
      [25] Pecci F, et al. Non-small-cell lung cancer: how to manage EGFR-mutated disease. Drugs Context. 2022;11:2022-4-1.
      [26] Fu, K, et al. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 15, 173 (2022). Doi: 10.1186/s13045-022-01391-4.

      CP-513519
      April 2025